10x Genomics Inc.

06/08/2026 | Press release | Distributed by Public on 06/08/2026 14:47

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders
The annual meeting of stockholders of 10x Genomics, Inc. (the "Company") was held on June 4, 2026 via live webcast (the "Annual Meeting"). At the Annual Meeting, there were present, virtually or by proxy, holders of 117,542,161 shares of the Company's Class A and Class B common stock, representing 198,815,518, or approximately 90.5%, of the 219,700,782 eligible votes, constituting a quorum. The matters submitted to a vote at the Annual Meeting and the final voting results of such matters were as follows:
Proposal 1 - Election of Directors
The Company's stockholders approved the election of three Class I directors, each to hold office for a three-year term expiring at the Company's 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or until his earlier resignation or removal. The final voting results were as follows:
Nominee Votes For Votes Against Abstentions Broker Non-Votes
Serge Saxonov 164,137,381 15,559,860 557,329 18,560,948
Benjamin J. Hindson 162,942,766 16,761,532 550,270 18,560,950
John R. Stuelpnagel 155,628,365 24,072,179 554,023 18,560,951
Proposal 2 - Ratification of Independent Registered Public Accounting Firm
The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026. There were no broker non-votes on this proposal. The final voting results were as follows:
Votes For Votes Against Abstentions Broker Non-Votes
197,719,939 458,231 637,346 -
Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers
The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 24, 2026. The final voting results were as follows:
Votes For Votes Against Abstentions Broker Non-Votes
176,677,540 2,828,730 748,296 18,560,952
10x Genomics Inc. published this content on June 08, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 08, 2026 at 20:47 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]